National Report - Results of the community-based Prospective Investigation Gauging Melasma Reduction with a New Treatment (PIGMENT Trial) reinforce the conclusion that the fixed triple-combination cream containing fluocinolone acetonide 0.01 percent, hydroquinone 4.0 percent, and tretinoin 0.05 percent (Tri-Luma Cream) is a safe and highly effective treatment for melasma. In addition, the study findings show improvement occurs quickly, extends to patients of all skin types managed in the setting of usual clinical practice, and is associated with significant improvement in quality of life, said Helen M. Torok, M.D.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.